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Abstract
Vitamin D deficiency is observed worldwide and represents a health hazard for mothers, infants and elderly persons. We 
know that many young Japanese women experience vitamin D insufficiency; however, there is a lack of knowledge regarding 
the serum 25-hydroxyvitamin D [25(OH)D] profile of pregnant Japanese women and of the association between maternal 
25(OH)D level and maternal bone mass during pregnancy and lactation. In this longitudinal study, 160 pregnant Japanese 
women were enrolled; of them, 68 have been followed-up from the first trimester through at least 1 year of breast-feeding. We 
estimated serum 25(OH)D levels, intact PTH levels, calcaneus quantitative ultrasound (QUS: T score) scores, bone mineral 
density at the distal one-third of the radius, dietary intakes according to the Food Frequency Questionnaire, and sunlight 
exposure times. We found that Vitamin D deficiency is prevalent in Japanese women, irrespective of pregnancy or lactation, 
and our analysis suggested that 25(OH)D levels and BMI in the first trimester were related to the lactating women’s bone 
mass from after delivery to 1 year after delivery.
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Introduction
Vitamin D deficiency is a well-known cause of rickets in 
neonates and infants [1]. Recently, vitamin D deficiency dur-
ing pregnancy and lactation has been associated with mater-
nal preeclampsia [2, 3] and gestational diabetes mellitus [4, 
5]. A study reported that children delivered by a mother 
with vitamin D deficiency may have a significantly lower 
bone mass at the age of 20 years [6] and that exposure to 
vitamin D deficiency in utero may have long-lasting effects 
on the infants. Moreover, it places the neonate at a higher 
risk for craniotabes [7], low birth-weight [8], preterm birth 
[9], and infections [10]. Many reports have been published 
on maternal vitamin D supplementation in an attempt to 
improve maternal and fetal outcomes [11–16]. However, 
how vitamin D deficiency during pregnancy and breast-
feeding affects maternal bone mass [17] has not yet been 
determined. To clarify the relationship between 25-hydroxy-
vitamin D [25(OH)D] concentration profiles and maternal 
bone mass, we carried out a prospective cohort study by 
following participants from pregnancy and during their first 
year of breastfeeding.
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Materials and methods
A total of 160 healthy Japanese women, who attended the 
Yoshikata Obstetrics and Gynecology Clinic (Yokohama, 
Japan) between November 2010 to February 2011 and who 
were up to 12 weeks pregnant and free from any under-
lying diseases and drug intake, which might affect bone 
metabolism, were enrolled in this study. The measurement 
was conducted within the limitation of recruiting early 
pregnant women from November to January (winter). We 
accommodated each pregnancy period, because the level 
of 25(OH)D varies seasonally [18] The participants were 
asked to visit us for testing in the first trimester (weeks 
8–12), second trimester (weeks 22–24), third trimester 
(weeks 32–34), delivery (3 days postpartum), 1 month 
postpartum, 6 months postpartum, and 1 year postpartum. 
A condition was that mothers breastfed their babies for at 
least 1 year, and any participants who weaned their babies 
before their first birthday were excluded from the analysis. 
We also measured 25(OH)D and intact-parathyroid hor-
mone (PTH) levels of 30 women who were neither preg-
nant nor lactating as the controls.
This joint research project was called the SKY (named 
after the three cities where joint research facilities were 
located: Sakado, Kobe, and Yokohama, Japan) pregnant 
cohort study. The Institutional Review Board at the Yoko-
hama City University School of Medicine (Yokohama, 
Japan) approved this clinical study, and all participants 
provided informed consent.
Measurements
Sunlight exposure
At each hospital visit, participants were asked to record 
sunlight exposure for the past 2 weeks, including details 
such as where they applied sunscreen and the extent of 
sunscreen use. We calculated the ratio of the part of the 
skin on which sunscreen was used; partially applied sun-
screen was defined as not exposed under sunlight. Sunlight 
exposure times were calculated from this information.
Dietary intake
Nutritional states were evaluated according to the Food 
Frequency Questionnaire (FFQ) [19, 20]. Participants 
filled out these forms during their clinic visits, and the 
Laboratory of Physiological Nutrition, Kagawa Nutri-
tion University (Sakado, Japan) analyzed the results. 
Participants were also questioned about using supple-
ments. Vitamin D, calcium, vitamin K, and the total calo-
rie intake of meals they had were calculated. Participants 
were not provided with any nutritional guidance.
Anthropometry
Height and body weight were measured at the initial visit. 
Body weights were recorded during every subsequent visit.
Serum 25(OH)D, intact parathyroid hormone 
(intact‑PTH)
Serum was kept frozen at − 30 °C until analysis. Serum 
25(OH)D was assayed with  LIAISON®  (LIAISON® N-TACT 
® PTH II Assay: DiaSorin, Stillwater, MN, USA) [21]. Intact-
PTH was measured at the Department of Hygienic Sciences, 
Kobe Pharmaceutical University (Kobe, Japan).
Bone ultrasound measurement
To avoid any radiation exposure during pregnancy, we meas-
ured the bone density by calcaneus quantitative ultrasound 
(QUS) using the Lunar A-1000 EXPRESS, GE Healthcare. 
Measurements were carried out in a temperature and humid-
ity-controlled room by one of three designated technicians. 
Results were derived in the form of broadband ultrasound 
attenuation (BUA), speed of sound (SOS), and stiffness. In 
this study, participants were evaluated with T scores of Stiff-
ness [22].
Bone mineral density (BMD)
After birth, in addition to QUS measurements, BMD of 
the distal third of the radius in the non-dominant arm was 
determined by dual-energy X-ray absorptiometry: DXA 
(DTX-200, Osteometer MediTech Inc). A single technician 
recorded all the measurements for BMD.
Statistical analysis
Data were analyzed at the Department of Hygienic Sciences, 
Kobe Pharmaceutical University (Kobe, Japan) and Yoshi-
kata Obstetrics and Gynecology Clinic using the  JMP® (SAS 
Institute, USA) statistical software program.
Results
Subjects’ characteristics
The characteristics of the participants at the point of enroll-
ments are shown in Table 1. Of the 160 pregnant women 
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entering the study, the following number of women were 
available for follow-up: 158 in the first trimester of their 
pregnancy (2 participants dropped out due to early-stage 
miscarriage); 147 in the second trimester (11 dropped out 
due to early-stage miscarriage or a change of address); 144 
in the third trimester (2 dropped out due to premature abrup-
tion, and 1 neonate had congenital malformations and was 
transferred to an advanced medical facility). Of the 142 par-
ticipants who gave birth, 1 suffered placental abruption and 
1 had a severely small-for-dates neonate who was required 
to transfer to an advanced medical institution. A total of 142 
participants were available for follow-up at 1 month postpar-
tum. Obstetric care is usually terminated at 1 month postpar-
tum in Japan. We provided accounts of further examination 
to 142 participants and obtained consent from 76 of them. 
At 6 months postpartum, 76 participants were available for 
follow-up and 68 were available at 1 year postpartum (8 
dropped out due to weaning). In this study, we analyzed the 
results of participants who could be followed until 1 year 
postpartum (Fig. 1.)
25(OH)D
All participant’s blood levels of 25(OH)D are showed in 
Table 2. The levels were 9.2 ± 3.6 ng/mL in the first tri-
mester, 8.3 ± 2.9  ng/mL in the second trimester, and 
10.6 ± 4.3 ng/mL in the third trimester. After delivery, they 
Table 1  Demographic and clinical characteristics of participants
BMI Body Mass Index
Variables Mean ± SD
Participants at baseline (n = 160)
 Age (year) 32.0 ± 3.7
 Height (cm) 159.2 ± 4.8
 Weight (kg) 51.5 ± 6.4
 BMI (kg/m2)
 First trimester (n = 158) 20.3 ± 2.2
 Second trimester (n = 147) 22.2 ± 2.3
 Third trimester (n = 144) 23.5 ± 2.4
 Delivery (n = 142) 24.2 ± 2.5
 1 month postpartum (n = 142) 21.4 ± 2.3
 6 month postpartum (n = 76) 20.5 ± 2.4
 1 year postpartum (n = 68) 19.8 ± 2.4
Measurement item at delivery (n = 142)
 Body weight gain at delivery (kg) 9.5 ± 3.3
 Infant birth weight (g) 3027.6 ± 338.1
 Infant birth height (cm) 49.4 ± 1.6
 Gestational age (weeks) 39 ± 1
 Primiparity (%) 32.5
Non pregnant lactating women (n = 30)
 Age (year) 30.8 ± 4.7
 Height (cm) 159.3 ± 0.0
 Weight (kg) 52.1 ± 7.5
 BMI (kg/m2) 20.6 ± 3.1
160 parcipants enrolled in study , Baseline measured 
158 parcipants have tesng 
[second trimester: weeks 22 to 24] 
[first trimester: weeks 8 to 12] 
2 miscarriage 
6 miscarriage 
5 relocated 
147 parcipants have tesng 
[third trimester: weeks 32 to 34] 144 parcipants have tesng 
Transferred to an advanced 
medical facility 
2 placental previa 
1 congenital malformaons 
142 parcipants gave birth 
Transferred to an advanced 
medical facility 
1 placental abrupon 
1 small-for-dates neonate 
142 parcipants were follow-up   [1 month postpartum] 
76 parcipants were follow-up   [6 months postpartum] 
68 parcipants were follow-up   [1 year postpartum] 
8 weaning 
Informed more examinaon 
76 parcipants consented 
Fig. 1  Flowchart of this cohort study
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were 10.1 ± 4.5 ng/mL at 3 days postpartum, 13.1 ± 5.0 ng/
mL at 1 month postpartum, 16.0 ± 4.8 ng/mL at 6 months 
postpartum, and 21.4 ± 5.7 ng/mL at 1 year postpartum. 
Throughout the entire observation period, 25(OH)D lev-
els were extremely low, and participants were estimated 
as either vitamin D deficient or insufficient. The group 
of non-pregnant and non-lactating women had levels of 
13.1 ± 4.6 ng/mL, which are as low as pregnant women.
68 women’s blood levels of 25(OH)D which could be 
followed until 1 year after delivery, were 9.4 ± 3.8 ng/
mL in the first trimester, 8.3 ± 2.8 ng/mL in the second 
trimester, 10.9 ± 4.7 ng/mL in the third trimester, and 
10.2 ± 4.4 ng/mL at delivery. Levels of 25(OH)D were 
12.9 ± 4.8 ng/mL at 1 month postpartum, 15.8 ± 4.8 ng/mL 
at 6 months postpartum, and 21.4 ± 5.7 ng/mL at 1 year 
postpartum. Analyzing the results with ANOVA revealed 
a statistically significant difference. We conducted the 
analysis using the HSD test of the Tukey–Kramer method; 
25(OH)D levels at 6  months postpartum and 1  year 
postpartum were higher than those in the first trimester 
(p < 0.0001), and those at 1 month postpartum were higher 
than those in the first trimester (p = 0.0002). The 25(OH)
D levels at 6 months postpartum and 1 year postpartum 
were higher than those at delivery (p < 0.0001), and so 
were those at 1 month postpartum (p = 0.0121) (Fig. 2a).
Intact‑PTH
Blood levels of intact-PTH, which were analyzed in all 
participants including non-pregnant and non-lactating 
women, are shown in Table 2. A total of 68 women’s 
blood levels of intact-PTH which could be followed until 
1 year after delivery, were at 35.9 ± 16.6 pg/mL in the 
first trimester, 33.9 ± 13.1 pg/mL in the second trimes-
ter and 36.6 ± 15.6 pg/mL in the third trimester. Intact-
PTH did not change significantly during pregnancy. A 
significant decrease from baseline was noted at delivery, 
dropping to 19.1 ± 11.6 pg/mL. However, the levels sig-
nificantly went up to 21.8 ± 13.5 pg/mL after at 1 month 
postpartum, 38.8 ± 16.7 pg/mL at 6 months postpartum, 
and 55.3 ± 21.4 pg/mL at 1 year postpartum. The levels 
remained within the normal limits throughout the entire 
study period. Non-pregnant and non-lactating women had 
levels of 56.5 ± 11.5 pg/mL. ANOVA analysis revealed 
a statistically significant difference (p < 0.0001). Moreo-
ver, intact-PTH levels at delivery and 1 month postpar-
tum were significantly lower than those in the first tri-
mester (p < 0.0001: Turkey–Kramer). Levels measured at 
1 year were significantly higher than those during the first 
Table 2  All participant’s blood levels of 25(OH)D and intact-PTH
Values are mean ± SD
25(OH)D (ng/mL) intact PTH (pg/mL)
First trimester (n = 158) 9.2 ± 3.6 35.7 ± 15.8
Second trimester (n = 147) 8.3 ± 2.9 35.4 ± 13.2
Third trimester (n = 144) 10.6 ± 4.3 36.9 ± 16.9
Delivery (n = 142) 10.1 ± 4.5 20.6 ± 12.7
1 month postpartum 
(n = 142)
13.1 ± 5.0 25.8 ± 18.1
6 months postpartum 
(n = 76)
16.0 ± 4.8 38.0 ± 16.2
1 year postpartum (n = 68) 21.4 ± 5.7 55.3 ± 21.4
Non-pregnant and non-
lactating women (n = 30)
13.1 ± 4.6 56.5 ± 11.5
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Fig. 2  a The blood levels of 25(OH)D which could be followed until 
1 year after delivery (n = 68): no significant change was found during 
pregnancy. The 25(OH)D levels were significantly higher at 1 month, 
6  months, and 1  year postpartum than the first trimester and deliv-
ery. The data are represented as mean ± SD. (++p value< 0.0001, +p 
value< 0.001 vs. first trimester, **p < 0.0001, *p < 0.05 vs. delivery; 
with ANOVA, by HSD test of Tukey–Kramer). b Intact-PTH levels 
during pregnancy and lactation. The intact-PTH level decreased at 
delivery, gradually increased during lactation, and reached approxi-
mately the same level as in the control group at 1 year postpartum. 
Compared with the first trimester, levels were significantly lower at 
delivery and 1 month postpartum, and significantly higher at 1 year 
postpartum (++p value < 0.0001 vs. first trimester). Levels were sig-
nificantly higher at 6  months, and 1  year postpartum than at deliv-
ery (**p value < 0.0001 vs. delivery; with ANOVA, by HSD test of 
Tukey–Kramer)
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trimester. The levels during pregnancy, at 6 months, and 
at 1 year postpartum were higher than the level at delivery 
(p < 0.0001: Turkey–Kramer) (Fig. 2b).
Participant’s dietary intake
Table 3 shows the information collected from the FFQ 
regarding the dietary intake of participants. The total energy 
intake and total calcium intake did not reach the Dietary 
Reference Intakes for Japanese individuals recommended 
by the Ministry of Health, Labor and Welfare.
Sunlight exposure times
Sunlight exposure in a time span of 2  weeks was of 
6.5 ± 10.5 h in the first trimester, 7.3 ± 11.8 h in the sec-
ond trimester, 7.3 ± 12.0 h in the third trimester, 4.8 ± 9.1 h 
at the time of delivery, 2.0 ± 4.0 h at 1 month postpartum, 
6.6 ± 10.2 h at 3 months postpartum, 7.2 ± 10.7 h at 6 months 
postpartum, and 8.9 ± 16.6 h at 1 year postpartum. Sunlight 
exposure time at 1 month postpartum was significantly 
lower than during the first trimester (p < 0.01: ANOVA, 
Tukey–Kramer HSD test). The rate of sunscreen use was of 
56.5% in the first trimester, 63.9% in the second trimester, 
64.3% in the third trimester, 72.0% at the time of delivery, 
66.7% at 1 month postpartum, 63.5% at 3 months postpar-
tum, 59.3% at 6 months postpartum, and 66.3% at 1 year 
postpartum. The reduced duration of sunlight exposure was 
attributed to the fewer opportunities to leave the house from 
the time before delivery to 1 month postpartum. Regard-
ing the lack of exposure to sunlight, 47% of participants 
were exposed to less than 3.5 h for every 2 weeks during 
pregnancy.
Calcaneus QUS: stiffness derived T scores
The average T scores of stiffness were noted in the first tri-
mester (101.3 ± 15.4%), second trimester (99.9 ± 17.8%), and 
third trimester (98.6 ± 16.7%), at delivery (94.3 ± 16.2%), at 
1 month postpartum (98.3 ± 16.6%), at 3 months postpartum 
(100.8 ± 16.8%), at 6 months postpartum (102.3 ± 19.1%), 
and 1 year postpartum (96.0 ± 17.5%). The results obtained 
with ANOVA did not show any significant change (Fig. 3a).
BMD at the distal third of the radius
The average value of the young adult mean (YAM) at each 
stage was 96 ± 11.2% at delivery (n = 140), 93 ± 11.6% at 
6 months postpartum (n = 76), 92 ± 11.0% at 1 year post-
partum (n = 68). The percentage changes in the BMD of 
participants who could be followed until 1 year postpartum, 
were − 4.1 ± 21.3% from delivery to 6 months postpartum 
and declined to − 3.1 ± 17.7% at 1 year postpartum (n = 68). 
ANOVA analysis did not show a significant change (Fig. 3b).
Factors affecting maternal bone mass extracted
Using the calcaneus QUS (T score) and BMD (YAM) as 
determinants, single regression analyses were performed for 
each of the following prognostic factors: 25(OH)D, intact-
PTH, BMI, age, calcium intake, vitamin D intake, vita-
min K intake, and sunlight exposure times. Both 25(OH)
D level and BMI were significant factors for bone mass at 
each stage. (25(OH)D: 0.003 < r2 ≤ 0.042, p < 0.05; BMI: 
0.017 < r2 ≤ 0.308, p < 0.001) (data not shown). Further-
more, as a result of multiple regression analyses using 
25(OH)D level and BMI as predictors of calcaneus QUS (T 
score) and BMD (YAM), BMI was a stronger factor (BMI: 
1.51 < t ≤ 4.31, p < 0.05) (data not shown).
BMI and 25(OH)D correlation with radius BMD (YAM)
We examined the longitudinal effects of 25(OH)D levels and 
BMI on BMD during lactation. Single regression analyses 
of the 25(OH)D levels of each period and BMD in lactation 
revealed that first trimester 25(OH)D levels were associated 
with BMD in lactation (at delivery: r2 = 0.068, p < 0.05; 
6 months after delivery: r2 = 0.088, p < 0.05; 1 year after 
delivery: r2 = 0.095, p < 0.05). No significant association 
with 25(OH)D levels in second or third trimester was evi-
dent (data not shown).
In this study, BMI during the first trimester was positively 
correlated with BMD in all after delivery stages (r = 0.49 at 
delivery, r = 0.54 at 6 months postpartum, and r = 0.47 at 
1 year postpartum). Based on this correlation, we performed 
a subgroup analysis of the low-BMI participants with a BMI 
lower than the median value (20 kg/m2) in the first trimes-
ter. Participants were also divided into two groups accord-
ing to the median 25(OH)D level (8.9 ng/mL) of the first 
trimester. As a result, in this low-BMI group, BMD in the 
high-25(OH)D group was significantly higher than that of 
the low-25(OH)D group over an entire period after delivery 
(p < 0.01 at delivery, p < 0.05 at 6 months postpartum and 
1 year postpartum: unpaired t test, Welch), whereas in the 
high-BMI group, we found no difference in BMD regarding 
25(OH)D levels (Fig. 4).
Discussion
We conducted a prospective cohort study to examine the 
25(OH)D profiles of Japanese pregnant and lactating women, 
and the association between 25(OH)D levels and maternal 
bone mass. Accordingly, two findings were revealed. First, 
25(OH)D remained extremely low throughout pregnancy 
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Table 3  The FFQ regarding the dietary intake of participants
a Dietary Reference Intakes for Japanese (2015) (supplement use) (by the Ministry of Health, Labor and Welfare)
Nutrition Data we got from participants could be followed until 
1 year postpartum (mean ± SD) (n = 68)
Dietary reference  intakesa
Total energy (kcal/day) Estimated energy requirement (EER)
 Trimester of pregnancy
  First 1623.4 ± 260.0 2000–2050
  Second 1680.9 ± 255.6 2200–2250
  Third 1622.8 ± 234.0 2400–2450
 Postpartum
  1 month 1753.0 ± 219.2 2300–2350
  3 month 1756.1 ± 285.3 2300–2350
  6 month 1769.7 ± 227.8 2300–2350
  1 year 1724.1 ± 251.6 2300–2350
 Non-pregnant-lactating women (n = 30) 1580.8 ± 236.9 1650–1750
Vitamin D intake (μg/day) Adequate intake (AI)
 Trimester of pregnancy
  First 8.9 ± 1.7 7
  Second 10.1 ± 1.7 7
  Third 9.8 ± 1.9 7
 Postpartum
  1 month 10.4 ± 2.2 8
  3 month 10.2 ± 2.1 8
  6 month 10.0 ± 2.2 8
  1 year 9.9 ± 1.8 8
 Non-pregnant-lactating women (n = 30) 9.0 ± 2.0 5.5
Calcium intake (mg/day) Estimated average requirement (EER)
 Trimester of pregnancy
  First 417.5 ± 117.5 550
  Second 480.1 ± 138.8 550
  Third 475.6 ± 153.3 550
Postpartum
  1 month 442.4 ± 97.6 550
  3 month 443.2 ± 106.4 550
  6 month 442.6 ± 101.4 550
  1 year 469.9 ± 117.5 550
 Non-pregnant-lactating women (n = 30) 368.0 ± 114.0 550
Vitamin K intake (μg/day) Adequate intake (AI)
 Trimester of pregnancy
  First 197.9 ± 85.2 150
  Second 195.9 ± 80.0 150
  Third 191.4 ± 74.0 150
Postpartum
  1 month 227.7 ± 101.9 150
  3 month 224.6 ± 100.4 150
  6 month 221.1 ± 135.6 150
  1 year 218.4 ± 106.7 150
 Non-pregnant-lactating women (n = 30) 211.2 ± 134.1 150
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and lactation in Japanese women. Levels in participants con-
sistently remained below 20 ng/mL from the first trimester 
of pregnancy to 6 months postpartum, which is defined as 
being vitamin D deficient [17, 18, 23]. At 1 year postpartum, 
levels in participants were still below 30 ng/mL, which is 
considered to be vitamin D insufficient. Second, maternal 
bone mass during pregnancy and lactation was found to be 
related to 25(OH)D levels and BMI in the first trimester. If 
women with low levels of both BMI and 25(OH)D become 
pregnant it seems impossible that their bone mass can be 
sustained during lactation.
Previous studies in other countries have found low levels 
of 25(OH)D during pregnancy and lactation [24–26]. When 
compared to the rest of the world, unfortunately, Japanese 
women’s 25(OH)D levels were substantially lower than 
women of the same generation from other countries. In 
order to confirm data reliability, 30 women were tested who 
lived in the same areas as the study subjects and who were 
neither pregnant nor nursing. Their 25(OH)D levels were as 
deficient as those of the pregnant women.
We investigated the relationship between 25(OH)D levels 
and sunlight exposure times, and a significant positive corre-
lation was noted at 6 months postpartum (r = 0.36, p < 0.01). 
Yokohama is located at 35.67° north latitude and 139.65° 
east longitude. Plugging these numbers into Holick’s rule 
[27], which calculates daily sunlight exposure times equiva-
lent to 25 µg (1000 IU/day) of vitamin D intake, the mini-
mally perceptible erythema (MED) irradiation equivalent to 
a quarter of the body surface area would require a minimum 
of 15 min per day (3.5 h in 2 weeks) of sunlight exposure 
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Fig. 4  Comparisons of BMD (YAM) between high-25(OH)D groups: 
25(OH)D at the first trimester > 8.9  ng/mL, and low-25(OH)D 
groups: 25(OH)D at the first trimester ≤ 8.9 ng/mL. a Subgroup anal-
ysis of the low-BMI participants: BMI in the first trimester ≤ 20 kg/
m2. BMD in the high-25(OH)D groups were significantly higher than 
that in the low-25(OH)D groups at all stages (*p < 0.05, **p < 0.01: 
unpaired t test, Welch). b Subgroup analysis of the high-BMI partici-
pants: BMI in the first trimester > 20 kg/m2. It’s showed no significant 
differences in BMD regarding 25(OH)D levels
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in Yokohama. The averages at each measured period except 
1 month postpartum were above the recommended num-
ber, and there is much variation in these values. Investigat-
ing the proportion of each participant’s average sunlight 
exposure time from the sum during pregnancy, we found as 
many as 47% of them exposed to sunlight for less than 3.5 h 
in 2 weeks. Young Japanese women generally use a high 
amount of sunscreen against UV rays to maintain a light 
complexion. Therefore, the limited exposure to sunlight in 
this population may be one of the causes of low 25(OH)D 
levels. Dawodu et al. have reported that pregnant women in 
the United Arab Emirates (UAE) cannot expose their skin for 
religious reasons and have extremely low levels of 25(OH)D 
[14]. Levels in pregnant women from the UAE and Japanese 
women who participated in this study are quite similar. Also, 
both are remarkably lower than data from other nations [28].
Calculations to determine vitamin D intake from meals 
using the FFQ method do satisfy The Ministry of Health, 
Labor and Welfare’s Dietary Reference Intakes for Japanese 
(estimated energy requirement) of 8 μg/day during preg-
nancy, and 9 μg/day during lactation. In this study, a signifi-
cant correlation was noted between the vitamin D intake and 
25(OH)D levels at 1 month postpartum (r = 0.39; p < 0.01) 
and 6 months postpartum (r = 0.34; p < 0.01).
Regarding 25(OH)D levels, there were no changes during 
pregnancy; however, during lactation, they increased up to 
1 year postpartum gradually. They were significantly higher 
than in the first trimester at 1 year postpartum. It may be 
because daily sunlight exposure times gradually increased 
since delivery to 1 year postpartum. Although the average 
vitamin D intake of the subjects in the present study was 
more than adequate (5.5 μg/day) according to the Dietary 
Reference Intake for Japanese 2015, formulated by Min-
istry of Health, Labor and Welfare, their 25(OH)D levels 
remained low.
These results suggest that current adequate vitamin D 
intake but with limited sun exposure may not be enough to 
attain sufficient vitamin D levels.
In addition, no significant differences in the 25(OH)D 
values were noted when women who resumed menstrua-
tion within 6 months postpartum were compared to those 
who did not resume menstruation within 6 months (data not 
shown). A recent study showed that race/ethnicity and BMI 
play an important role in pregnancy bone health and that a 
dose effect of vitamin D supplementation does not support 
bone health [16]. The effect of BMI was coincident with our 
findings. In another study, vitamin D supplementation dur-
ing pregnancy was associated with a reduced risk of SGA 
and improved infant growth without risk of fetal or neo-
natal mortality or congenital abnormality [29], increased 
circulating 25(OH)D level, birth weight, and birth length, 
but not with other maternal and neonatal outcomes [30]. 
Maternal vitamin D supplementation from mid-pregnancy 
until birth or 6 months postpartum did not improve fetal 
or infant growth [31]. Pre-pregnancy vitamin D supple-
mentation may prevent the disorder, considering the result 
that the 25(OH)D level in the first trimester was associated 
with maternal bone mass in our study. Four quadrants by 
the median values of 25(OH)D and BMI in the second or 
third trimester were formed. Higher levels of second tri-
mester 25(OH)D were associated with higher BMD during 
lactation, in the low BMI group, but the difference was not 
significant. Furthermore, no effect was observed in the third 
trimester. Although the reason why only first trimester levels 
of 25(OH)D affected maternal BMD during lactation in the 
low BMI group is unclear from the findings of our study, the 
fact that BMI increasing as pregnancy progresses, greatly 
affecting bone mass, maybe one reason.
Maternal bone mass was measured by calcaneus QUS to 
avoid exposing the fetuses to X-rays during pregnancy. In 
our study, no significant change was noted during pregnancy 
and lactation. Several papers in the literature have reported 
decreases in the QUS value at delivery [32–36]. Instead, our 
results agree with the suggestions of literature reports, so 
there is no difference in QUS values during lactation based 
on how long a woman breastfeeds her baby [32, 36]. QUS 
values could be maintained regardless of whether the study 
participant engaged in long-term lactation. Although, results 
of QUS were affected by the change in body fluid volume 
and edema during pregnancy bone quality may reflect them. 
The use of QUS remains to be further studied.
Multiple papers have reported that the radius BMD 
decreases during postnatal breastfeeding [37–42]. We 
observed a similar finding in our study: BMD tended to 
decrease at 1 year postpartum. In a cohort study of partici-
pants for up to 9 months postpartum, BMD decreased [43]. 
However, if breastfeeding continued for less than 4 months, 
BMD recovered to pre-pregnancy levels, and the duration 
of breastfeeding was deemed to affect this recovery pro-
cess. Since our participants were lactating, radius BMD 
also showed a declining tendency at 1 year postpartum 
(Fig. 3b). Kurabayashi et al. indicated that osteoporotic or 
osteopenic women identified with the puerperal scans were 
still osteopenic after 5–10 years, as assessed by puerperal 
scans recorded 5–10 years later, and they were associated 
with a significantly lower BMI compared to normal women 
[44]. In the long term, appropriate BMD and BMI signify a 
good condition in reproductive life. Compared with 25(OH)
D level, BMI had a stronger association with maternal bone 
mass in this cohort. This may be reason why 25(OH)D level 
was not relevant in the high BMI group (Fig. 4b).
Obstetric outcomes revealed an infant birth weight of 
3028 ± 339 g (mean ± SD) including 7 low birth weight neo-
nates (4.93%), but there was no correlation with 25(OH)D 
levels. Craniotabes was noted in two cases (0.6%), and there 
were no cases of preeclampsia in this cohort.
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In our prospective cohort study where 68 participants 
were followed from early pregnancy throughout 1 year post-
partum, changes in 25(OH)D levels and bone mass over time 
were shown during long-term breastfeeding. Maternal bone 
mass was found to be associated with 25(OH)D levels and 
BMI during this period. An acknowledged low BMI is risky 
in maintaining bone mineral density [45], furthermore, low 
levels of 25(OH)D are even more harmful. It is important for 
maternal bone health that 25(OH)D and BMI levels during 
the onset of pregnancy are appropriate.
There were several limitations in this study that should 
be acknowledged. First, maternal baseline data before preg-
nancy were not known. Also, we did not measure estrogen, 
1,25(OH)D, or PTHrP levels, and the mechanism behind 
the changes in 25(OH)D over time could not be elucidated. 
These results did not necessarily reflect the condition of all 
Japanese women, because we were limited to participants 
living in an urban area.
In conclusion, we found that Vitamin D deficiency is 
prevalent in Japanese women, irrespective of pregnancy 
or lactation. Our analysis suggested that the low levels of 
25(OH)D and BMI in the first trimester were risk factors 
for a low BMD during lactation. Therefore, providing direc-
tion to expectant mothers to increase blood concentrations 
of 25(OH)D and achieve an appropriate weight in the early 
pregnancy phase are vital to maintaining a proper maternal 
bone mass.
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